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ABSTRACT 
Epigenetics - defined as the inheritable changes that are 
not accompanied by alteratio ns in DNA sequence - is a 
rapidly growing field and its research is being proposed for 
implementation into the clinical setting. Indeed, advances in 
epigenetics and epigenomics (which focuses on the analysis 
of epigenetic changes across the entire genome) can be 
applied in pharmacology. 
Specifically, its application has given rise to a new 
specialty ca lled pharmacoepige netics, which st udies the 
epigenetic basis for the variation between individuals in 
their drug response. Pharmacoepigenetics can become 
o ne of the tools for the personalised medicine approach, 
with potentially safer treatments and less side-effects 
on the horizon. 
INTROC>\,CTlvN 
Several research studies have shown that patients displaying 
similarities in disease expression may produce distinct 
responses to the same drug treatments. Although factors 
such as age, body-surface area, d isease stage, gender or 
weight may be partly responsible, personalising treatments 
based on these factors does not complete ly tackle this 
problem. In fact, medical specialists are increasingly shifting 
in the direction of patient genomic data for selecting optimal 
treatments in specific scenarios. In addition, a g rowing 
body of evidence has revealed that epigenetics also p lays a 
significant role in ascertaining the efficacy and safety of drug 
treatments in patients.1 
Developments in epigenomics, including advances 
made by the Human Epigenome Project, have laid the 
foundations for the growing field of pharmacoepigenetics. 
Pharmacoepigenetics o riginally arose as a discipline to 
research how e pigenetic patterns influence patients' drug 
responses. However, there is now another development 
for pharmacoepigenetics: therapeutic epi.drugs designed 
to initiate changes in the epige nome, to reduce the 
symptoms or progression of a disease for individual 
patients. Notwithstanding the substantial knowledge gap 
that exists between our understanding of clinical treatments 
and epigenetic modifications on d rug metabolism 
mechanisms, pharmacoepigenetics is a developing field 
with the potentia l to bridge the gap and be of great utility in 
personalised medicine. 
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PHARMACOEPIGENrrrs AND HUMAN DISEASES 
Underlying the d evelopment of effective epigenetic 
therapies are the epigenetic mechanisms and the proteins 
involved, including DNA methylation, histone modifications 
and regulatory miRNA.2 DNA methylation is closely 
linked with histone modifications, and their interaction is 
funda mental in controlling genome functioning by altering 
chromatin architecture. In addition, a group of miRNAs 
known as epi·miRNAs can d irectly target effectors of the 
epigenetic machinery, including DNA methyltransferases, 
histone deacetylases (HDACs), and polycomb repressive 
complex genes. Such epigenetic-miRNA interaction results 
in a new layer of complexity in gene regulati.on, opening 
up new avenues. 
In this article, we will discuss briefly how these 
mechanisms link to d iseases such as cancer, heart and 
neurodegenerative d iseases, autism, bipolar d isorder, 
depression and immunological disorders. 
Cancer 
It is true that, when it comes to the epigenetic aberrations of 
particular cancers at d ifferent steps in tumour d evelopment, 
a lot of work sti 11 needs to be carried out. It is also true, 
however, that there is a general understanding of which 
modifications lead to irregular gene expression in relation 
to the d ifferent types of cancer. In fact, these epigenetic 
biomarkers are being applied in t he clinic as a tool to 
fi rst detect cancer and classify the tumour, and then to 
understand the d rug response to treatment. 
As an example, the DNA methyltransferase inhibitors 
azacitidine and decitabine have been approved by FDA 
for the treatment of patients with acute myeloid leukaemia, 
chronic myelomonocytic leukaemia and higher-risk 
myelodysplastic syndromes; the latter being a group of 
cancers where blood cells from the bone marrow do not 
mature properly into healthy blood cells.3•4 
Azacitidine, together with another drug called entinostat, 
has also been used in clinical trials of non-small-cell lung 
carcinoma.5 In this particular study, 4 out of 19 patients 
had major objective responses to anticancer therapies 
given d irectly after epigenetic therapy. Entinostat, a HDAC 
inhibitor, prevents gene silencing by allowing access to the 
transcription machinery. Entinostat has also been shown 
to be a promising treatment for patients with advanced 
breast cancer. 6 
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MiRNA-based therapeutic strategies have also been 
applied in cancer. For example, a new miRNA drug 
candidate called RGLS5579 that targets miR-1 Ob has been 
announced for pote ntial trials in patients diagnosed with 
glioblastoma multiforme, one of the most aggressive forms 
of brain cancer.7 
Heart Disease 
In the developed world, mortality and morbidity from 
cardiovascular diseases (CVDs) represent a la rge burden 
to society.8•9 CVDs such as atherosclerotic cardiovascular 
disease, cardiomyopathy, congenital heart d isease, heart 
fail ure. and hypertensive heart disease are now being 
tackled as much more multifaceted disorders. !I ndeed, the 
epigenetic research in this field is now more prevalent and 
histone modifications and miRNAs have also b.een found to 
have a key role in heart disease.10 
In 201 6, Somanna et al. published the findings of their 
study which used the HDAC inhibitors Trichostatin A and 
Mocetinostat to show that targeting HDACs weakens the 
pro-fibrotic and pro-inflammatory effects of angiotensin 
(Ang)-11 on adult mouse cardiac fibroblasts.11 In addition, 
there is an increasing number of publicati.ons showing that 
miRNAs play a significant role in numerous aspects of heart 
fai lure. One such study is that by Yang et al. (2019), who 
found that miRNA-1 9b-1 reverses ischaemia-induced heart 
fail ure by inhibiting the apoptosis of cardiomyocytes.12 In 
a different study, Verjans et a l. (2019) identified miRNAs as 
multi-cellular reg ulators of different processes that cause 
cardiac d isease. Specifically, they characterised formerly 
undescribed roles of miRNAs in fibrosis, hypertrophy 
and inflammation, and ascribed novel effects to many 
well-known miRNAs.13 
Neurodegenerative Disorders 
Brain disorders with a vascular and/or neurodegenerative 
constituent are a common problem worldwide. 
One way in which this could be mitigated is through 
pharmacoepigenetics. 
DNA methylation could be restored, for instance, to 
regenerate the metabolic pathways d isturbed by DNA 
hypomethylation, which is li nked with the progression of 
some of the most widespread neurodegenerative disorders, 
including Alzheimer's and Parkinson's disease. Indeed, 
the ability of S-adenosyl-L-methionine and the B vitamins, 
includ ing folic acid, to restore methylation, together with 
their brain protective properties, makes them good diet 
supplements for treating these d iseases. Currently, vitamin 
B6 and fol ate are proposed for clinical trials to ascertain 
whether these interventions could possibly decrease 
cognitive impairment in patients with Alzheime r's disease.14 
HDAC inhibitors could also restore histone deacetylation, 
which is a shared feature of numerous neurodegeneratlve 
processes. In animal models, several HDAC inhibitors 
under d evelopment offer beneficial effects for cognitive 
and memory levels of Alzhe·i mer's and Parkinson's diseases. 
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However, only nicotinamide, sodium phenyl butyrate and 
valproic acid are in clinical trials as epidrugs for treating 
neurodegeneration.14•1s 
MiRNAs also play a role here. For instance, the 
overexpression o f miR-12416 and miR-19517 decreases 
the levels .of the -amyloid (A ) plaques, which are known 
to cause the neurodegeneration in Alzheimer's disease. 
In addition, miR-323-3p18 has been found to decrease 
neuroinflammation related to Alzheimer's d isease. Other 
non-coding RNAs, such as miR-34b/c, miR-132, and miR· 
221, are also possible biomarkers and therapeutic targets 
for Parkinson's d isease14,19. 
Autism Spectrum Disorder 
Autism spectrum disorder (ASD) is used to describe 
development disorders caused by a combination of 
genetic and environmental factors. Recently, the multigenic 
condition of ASD has been speculated to depend on 
epigenetic effects2<>, although th is remains unclear. 
For this reaso n, pharmacoepigerietics in ASD is still in 
its early stages. While research on epigenetic predictors of 
drug response is rare in ASD, the data on the develo pment 
of epidrugs is encouraging. DNA methyltransferase 
inhibitors have been found to reactivate repressed g enes in 
autism-associated genetic conditions, and more precisely, 
RNA-therapeutic ta rgeting genes were used to reactivate 
MeCP2, which is a candidate gene of ASD. In an imal studies, 
HDAC inhibitors have also been shown to enhance cognitive 
impairment and social behaviour.21 
Bipolar Disorder 
Studies have also been investigating the role of epigenetic 
mechanisms in bipolar d isorder and its treatment. Some 
of these mechanisms have been shown to be involved in 
the action of antidepressants, antipsychotics and mood 
stabilisers used for treating patients with bipolar disorder.22 
In a paper published in 2015, Backlund et al. investigated 
whether DNA methylation levels vary between healthy 
controls and bipolar patients when treated with e ither 
lithium or a combination of lithium and valproate, both of 
which are mood stabilisers. The authors found that lithium 
in monotherapy was li nked to hypomethylation, whereas 
lithium and valproate displayed a hypermethylated pattern 
when compared to lithium alone.23 This suggests that the 
choice of treatment in bipolar disorder may lead to different 
levels of DNA methylation. However, more research is 
necessary to understand its clinical sign ificance. Having 
said that, these epigenetic biosignatures could event ually 
revolutionise this field and benefit patients and clinicians 
alike in the future. 
Depression 
Major depressive disorder has become a worldwide 
proble m, with more than 503 of those on an initial 
antidepressant course not showing symptom remission. A 
genetic basis for the pathophysiology of major depressive 
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disorder has been strongly indicated in research studies, 
but despite these breakthroughs, no biomarke rs have 
been satisfactorily validated in treatment responses from 
clinical practice.2' 
New evidence from both human and animal model 
studies indicates a prominent role of epigenetic marks, such 
as histone modifications and DNA methylation, in predicting 
response to antidepressants. For example, epigenetic 
modifications of the genes SLC6A4, IL 11 and BDNF are 
demonstrating encouraging signs as biomarkers to predict 
antidepressant response.2s 
Immunological Disorders 
It has been shown that altered epigenetic patterns 
also play an important role in the d evelopment and 
pathophysiology of immuno logical d isorders, especially 
autoimmune diseases.26 
Indeed , HDAC inhibitors have been used in autoimmune 
disord ers, such as rheumatoid arthrit is (RA), systemic lupus 
erythematosus and systemic onset juvenile idiopathic 
arthritis.21.2s For example, a study revealed a new molecular 
mechanism by which the HDAC inhibitor Trichostatin A can 
disturb inflammatory cytokine production in RA synovial 
cells, suggesting that targeting HDACs may be useful in 
suppressing inflammation in RA in a clinical setting .29 
It has also been suggested that DNA methylation 
contributes to the developm ent of RA, however, with 
contradicto ry and unsatisfactory results. Studies have also 
shown that circulating cell-free methylated DNA in blood 
offers a non-invasive •liquid biopsy", providing a template 
for assessing molecular markers of diseases, including 
RA. Epigenetic therapies controlling autoimmunity may 
therefore find far-reaching implications for the d iagnosis and 
management of RA.» 
We know that responses to t herapeutic treatments 
are greatly dependent on our individual genomic and 
epigenom ic profi les, and so personalised treatments 
ideally should be governed by pharmacogenetic and 
pharmacoepigenetic method s for optimal efficacy. However, 
because the epigenetic machinery is versat ile, manipulations 
of epigenetic aberrat ions may lead to drug resistance. 
In the emergent field of pharmacoepigenetics, there 
is a current lack of information regarding the lo ng-term 
consequences of epidrugs exploiting targets w ith no 
real cell sp ecificity. In fact, procedures must first integrate 
pharmacoepigenetic studies in order to evaluate safety 
concerns and treatment efficacy in developing drugs and 
subsequent clinical trials. 
Despite recent major strides in the field of 
pharmacoepigenetics, it is only after further investigation 
that we will fully understand the role of epigenetic 
modifications in human health, such that we can harness its 
potential power for personal ised treatment of disease. 
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